Company Overview and News

213
Walgreens-GE Faceoff: How Impactful is it for Dow Investors?

5h zacks
Walgreens Boots Alliance (WBA - Free Report) has achieved a historic feat yesterday on emerging as the youngest participant on the Dow Jones Industrial Average (DJI) or DJIA. This is a momentous exploit not just because this goliath stock has entered the world’s most coveted index but more so for dramatically replacing Dow’s oldest member, General Electric Company (GE - Free Report) . With this success, Walgreens stalled GE’s uninterrupted run on the exchange for 110 long years.
GEC GE RAD WBA MS.PRE MS.PRF MS.PRG CVS MS.PRA MS.PRI MS.PRK GNE MS AET

347
Will Amazon's Entry Into Healthcare Disrupt the Market?

6h zacks
The much talked about and widely speculated foray of Amazon.com, Inc. (AMZN - Free Report) with Berkshire Hathaway Inc. (BRK.B - Free Report) and JP Morgan (JPM - Free Report) into the healthcare space is shaping up, with the appointment of the CEO of their healthcare company.
BRK.A AMZN RAD WBA CI CVS AET UNH

98
Amazon-Berkshire-JP Morgan health initiative makes an out-of-the-box choice for CEO - MarketWatch

20h marketwatch
Dr. Gawande has an ‘expert’s knowledge, a beginner’s mind, and a long-term orientation,’ Amazon CEO Jeff Bezos said
ATHTF BRK.A GEC GE WBA GNE ANTM CVS UNH ANTX

130
SA Interview: Chris DeMuth Jr. On First United And ETF Reconstitutions

2018-06-20 seekingalpha
Chris DeMuth Jr. is the founder of Rangeley Capital, an investment firm that focuses on event driven, value-oriented investment opportunities.
HNNA BBX TWX NXPI CVS TWC FUNC T AUBN ZN CI GNW AET JASO

52
Humana, Walgreens Team Up to Provide Better Senior Care

2018-06-20 zacks
Humana Inc. (HUM - Free Report) has decided to collaborate with Walgreens for providing better primary and other services to senior citizens via primary care clinics. Notably, Walgreens is a provider of trusted care, included in the Retail Pharmacy USA Division of Walgreens Boots Alliance (WBA - Free Report) . This alliance is part of the ongoing and shared commitment of both companies to the health and well-being of the Kansas City community.
WBA HUM CVS AET

35
Amazon, Berkshire, JPMorgan name Atul Gawande CEO of healthcare venture

2018-06-20 malaymail
NEW YORK, June 20 — Berkshire Hathaway Inc, Amazon.com Inc and JPMorgan Chase & Co today named Atul Gawande, a prominent medical professor who has criticised his industry’s practices, to lead their joint healthcare company.
BRK.A CVS

115
Dimon, Bezos, Buffett tap Atul Gawande for new healthcare firm

2018-06-20 livemint
New York/Mexico City: Atul Gawande, a surgeon and journalist who has written extensively about the US failure to grapple with rising healthcare spending, has been named to head a new health venture for Amazon.com Inc., Berkshire Hathaway Inc. and JPMorgan Chase & Co.
BRK.A CI CVS AET

158
5 Reasons Disney And Comcast Will Likely Crush The Market In The Future No Matter Who Buys Fox

2018-06-20 seekingalpha
Thanks to tax reform and the approval of the AT&T/Time Warner deal, merger mania is now in full swing.
FOX T TMUS CMCSA TWX VZ NFLX CVS TWC FOXA AET DIS

35
UPDATE 1-Amazon, Berkshire, JPMorgan name Atul Gawande CEO of healthcare venture

2018-06-20 reuters
(Reuters) - Berkshire Hathaway Inc, Amazon.com Inc and JPMorgan Chase & Co on Wednesday named Atul Gawande as the chief executive officer of their health venture.
BRK.A CVS

35
Amazon, Berkshire, JPMorgan name Atul Gawande CEO of healthcare venture - Channel NewsAsia

2018-06-20 channelnewsasia
Berkshire Hathaway Inc, Amazon.com Inc and JPMorgan Chase & Co on Wednesday named Atul Gawande as the chief executive officer of their health venture.
BRK.A CVS

55
Tuesday’s Biggest Winners and Losers in the S&P 500

2018-06-19 247wallst
June 19, 2018: The S&P 500 closed down 0.4% at 2,762.57. The DJIA closed down 1.2% at 24,699.46. Separately, the Nasdaq was down 0.3% at 7,725.58.
BOE CVS BA

119
Anthem Boosts Integrated Care With Aspire Health Buyout

2018-06-19 zacks
Anthem, Inc. (ANTM - Free Report) has completed the acquisition of Aspire Health, a non-hospice, community-based palliative care provider. The deal is aimed at providing unique and innovative medical care to the community outside hospitals.
CI ANTM CVS AET

7
Global indexes drop as Trump threatens more China tariffs

2018-06-19 moneycontrol
Global stock markets fell today after President Donald Trump threatened to put tariffs on another USD 200 billion in imports from China, and the Chinese government said it would retaliate. The Dow Jones industrial average lost 370 points, or 1.5 percent. The Hang Seng index in Hong Kong lost 2.8 percent. Major stock indexes in Asia and Europe also took sharp losses.
NEE.PRI NEE.PRJ NDAQ NEE.PRC NEE.PRQ NEE.PRR CVS FMI NEE

7
Global indexes drop as Trump threatens more China tariffs

2018-06-19 nzherald.co.nz
NEW YORK (AP) — Global stock markets fell Tuesday after President Donald Trump threatened to put tariffs on another $200 billion in imports from China, and the Chinese government said it would retaliate.
NEE.PRI NEE.PRJ NDAQ NEE.PRC NEE.PRQ NEE.PRR CVS FMI NEE

217
5 Top Stocks to Gain From Escalating Trade War Tensions

2018-06-19 zacks
U.S. President Trump has threatened to impose further tariffs on Chinese goods, while Beijing warned it would retaliate. This has heightened the trade spat between the two of the world’s largest economies. Investors, naturally, have turned nervous as earnings of companies could be at risk in the event of a global trade war.
WFCNP PSA.PRA ROP PSA.PRB FB WFC.PRL WFC.PRJ GOOG PSA.A CVS AYI.WI VZA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN CSX PSAXZ PSA.PRG WFC.PRY PSA.PRE WFC.PRX WFC.PRW PSA.PRF AAXN ROK PSA.PRC WFC.PRV PSA.PRD WFC WFC.WS AYI PSA.PRY PSA.PRZ PSA.PRW PSA.PRX PSA.PRU PSA.PRV PSA PSA.PRS PSA.PRT BABA INTU GOOGL DG VZ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to CVS / CVS Health Corporation on message board site Silicon Investor.

cvs CVSN: ChromaVision Medical Sys.
ChromaVision Med. Sys. (CVSN) CVS Corp
CUSIP: 126650100